Archive · 24 Jul 2025
Dr. Reddy's Shares Rise Following Q1 Results, Analyst Ratings Mixed
Dr. Reddy's Laboratories, a company that makes medicine, saw its stock price go up by 3%.
This happened after they shared their financial results for the first three months of the year.
The company made more money than last year, but some financial experts are not sure if the company will do well in the future.
Some experts think the stock price should stay the same or even go down, while others think it should go up.
The difference of opinion is because the company has been losing money in the US.
However, there are expectations that new medicines will help the company to improve in the future.
Dr Reddy's Laboratories (DRL) shares increased by 3% following the release of the company's Q1 results.
DRL's PAT increased by 2% year-over-year to Rs 1,417.8 crore for Q1 FY26.
Brokerage firms have mixed views on DRL due to margin pressures and global market factors.
HDFC Institutional Equities maintained a 'Reduce' rating with a target price of Rs 1,240.
JM Financial retained a 'BUY' rating with a target price of Rs 1,521, remaining optimistic about DRL's prospects.
- Who
- Dr Reddy’s Laboratories Ltd (DRL).
- What
- Shares of Dr Reddy’s Laboratories Ltd (DRL) increased by 3% after Q1 results.
- When
- Shares increased in Friday’s trade.
- Where
- On the BSE.
- Why
- Due to a 2% YoY increase in PAT and mixed views on the stock's prospects.
Negative Outlook
Positive Outlook
Stock Rating
Negative Outlook
HDFC Institutional Equities maintained a 'Reduce' rating, citing concerns.
Positive Outlook
JM Financial retained a 'BUY' rating, citing the 'larger story' remains intact.
Target Price
Negative Outlook
HDFC set a target price of Rs 1,240.
Positive Outlook
JM Financial set a target price of Rs 1,521.
- Stock Increase
- 3.2%
- Share Price
- Rs 1,287.90
- Previous Close
- Rs 1,247.55
- PAT (Q1 FY26)
- Rs 1,417.8 crore
- HDFC Target Price
- Rs 1,240
- JM Financial Target Price
- Rs 1,521